330 filings
Page 9 of 17
6-K
1uxej
25 Feb 19
Aurinia Pharmaceuticals Inc. 6-K
7:00am
6-K
bg3qs9x
22 Jan 19
Aurinia Pharmaceuticals Inc. 6-K
7:00am
6-K
dipn3 nbej2
30 Nov 18
Current report (foreign)
5:27pm
SUPPL
ljy0b9
30 Nov 18
Supplemental materials (foreign)
5:23pm
6-K
tae33
8 Nov 18
Current report (foreign)
4:04pm
6-K
rwsv8naei 8vhdk6wh
8 Nov 18
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
4:02pm
6-K
v549c4p8yusz
25 Sep 18
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
4:04pm
6-K
2tkxj
9 Aug 18
Current report (foreign)
4:05pm
6-K
fanaa i8jk
9 Aug 18
Aurinia Reports Second Quarter Financial Results and Operational Highlights
4:03pm
6-K
1m4 vx0hhtqrwziiv
11 Jul 18
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
4:01pm
6-K
62h8u2j1m
25 Jun 18
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin
11:32am
6-K
1n3f7t
22 Jun 18
Aurinia Announces Results of Annual General Meeting
4:30pm
S-8
5osl y74e
8 Jun 18
Registration of securities for employees
5:16pm
6-K/A
okrw0i
17 May 18
Current report (foreign) (amended)
12:00am
6-K
yvkbk2
16 May 18
Notice of Annual General Meeting of Shareholders
4:14pm
6-K
862jj2 0qy560jp
10 May 18
Current report (foreign)
4:06pm
6-K
rloaz
10 May 18
Aurinia Reports First Quarter Financial Results and Operational Highlights
4:03pm
SUPPL
4u2eppj36lh l6njw
6 Apr 18
Supplemental materials (foreign)
12:00am
EFFECT
b499ub8zi h3
29 Mar 18
Notice of effectiveness
12:00am
F-10/A
6m1pjqpf mg74qsbtmh
26 Mar 18
Registration of securities (Canada) (amended)
12:00am